Grazyna Szymanska Schellenberg

Grazyna Szymanska Schellenberg serves as the President of Apeiron Synthesis, Inc. since January 2014, providing strategic solutions in olefin metathesis catalysis for the pharmaceutical, agrochemical, and flavor and fragrance industries. Szymanska Schellenberg is an active member of the New England Women in Science Executives Club (NEWISE) since December 2014 and Mass Medical Angels (MA2) since April 2011, both organizations promoting leadership and investment in life sciences and healthcare. Previously, Szymanska Schellenberg held leadership positions including Managing Director at Golden Seeds, focusing on women-centric business startups, and VP of Corporate Development at ViThera Pharmaceuticals, dedicated to innovative treatments for inflammatory bowel disease. With earlier roles at TEI Biosciences, Tolerx, Curis, and Creative BioMolecules, as well as research experience at Boston College, Szymanska Schellenberg holds a Ph.D. in Biochemistry from the Polish Academy of Sciences and an MS in Molecular Biology from the University of Warsaw.